Invest in the world's first GLP-1 and weight loss ETF
$HRTS ETF
Learn more
David K. Song, MD, PhD, CFA

David K. Song, MD, PhD, CFA

David Song, Investment Partner, has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton.
Find me on:

Recent Posts

Five observations on ASCO 2024

I have been attending the American Society for Clinical Oncology (ASCO) for well over a decade. Some years there are fireworks with step function...

Investing in biotech stocks: The case for active ETFs

While we feel the ideal approach should start with a top-down segmentation of the life sciences landscape, in our opinion a bottom-up approach to...

Investing in biotech stocks: The need for a targeted approach

Historically, investing in life sciences through public equity has resulted in a choice between broad healthcare funds or slightly narrower but still...

Investing in biotech stocks: Opportunities & challenges

We believe life sciences are an important allocation in any portfolio. Yet despite its historical outperformance of the broader market, executing an...

The Next 10 Weight-Loss Drugs: Life After GLP-1?

Key Takeaways: GLP-1 drugs have pioneered obesity medication. Yet the race is on for the next generation, and we explore 10 promising new drugs in...

Immuno-oncology’s Second Act

Keytruda (Pembrolizumab) is the world’s biggest drug by sales, on track for more that $24bn in sales in 20231. The drug targets programmed cell death...

Radiopharmaceuticals: Transforming Cancer Care

Radiopharmaceuticals, or radioligand therapies, stand at the forefront of cancer treatment innovation. These therapies employ radioactive compounds...

Pursuing A Better Way To Invest In Life Sciences

We believe life sciences are an important allocation in any portfolio. Yet despite its historical outperformance of the broader market1, executing an...

Neuroscience and Mental Health: the most unmet need in life sciences

By many measures, neurological disorders remain the final frontier of life science research. Recent breakthroughs offer hope that we are at a turning...

Cell therapies - Revolutionizing Cancer Treatment

In oncology, cell therapy is a groundbreaking approach that involves using engineered immune cells, often sourced from the patient, as a "living...

The Next Generation of Cardiovascular Drugs

The cardiometabolic space is more than just the obesity revolution. Although GLP-1 weight loss drugs, like Wegovy, could modify cardiovascular...

Liquid Biopsies - Revolutionizing Cancer Diagnosis

Liquid biopsies, a cutting-edge diagnostic tool, are changing the landscape of cancer detection. They harness bodily fluids, such as blood, to...

Investing in the Obesity Epidemic: The Weight Loss Drug Revolution

Cardiovascular and metabolic diseases are a vast chronic burden on patients and society and the leading cause of death globally[1]. However, recent...

Investor's Guide to the Oncology Revolution Webinar Replay

Watch our latest webinar to learn about the exciting investment opportunities and challenges within the rapidly evolving field of cancer therapeutics...

Investing in oncology: a biotech revolution in research, diagnosis, and treatment of cancer

Cancer will affect one in every two people in their lifetime. Yet, oncology is on the brink of a revolution, which we expect will trigger a material...

No results found